Targeting immune response regulators in Familial Adenomatous Polyposis
Immunoepigenetic targeting of MHC regulators in FAP
This study is looking at ways to boost the immune system in people with Familial Adenomatous Polyposis (FAP) by using a mix of current medications and a new drug to help the body better recognize and fight off precancerous cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11049070 on NIH RePORTER |
What this research studies
This research investigates how to enhance the immune response in patients with Familial Adenomatous Polyposis (FAP) by targeting specific proteins involved in antigen presentation. The approach involves using a combination of existing medications and a new drug to increase the expression of major histocompatibility complex (MHC) proteins, which are crucial for the immune system to recognize and attack cancer cells. By administering these treatments, the goal is to improve the immune system's ability to detect and eliminate precancerous lesions before they develop into cancer. The research will involve both human and animal models to assess the effectiveness of these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Familial Adenomatous Polyposis who are at risk for developing colorectal cancer.
Not a fit: Patients without a diagnosis of Familial Adenomatous Polyposis or those who do not have adenomatous polyps may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immune responses in FAP patients, potentially preventing the progression of adenomas to colorectal cancer.
How similar studies have performed: Previous research has shown promise in using immune modulation strategies to enhance cancer treatment, suggesting that this approach may also be effective for FAP.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Dashwood, Roderick H — Texas A&m University Health Science Ctr
- Study coordinator: Dashwood, Roderick H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.